Dyne Therapeutics (DYN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Muscle Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), 21.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why Dyne Therapeutics (DYN) Is Back In The Spotlight
- Dyne Therapeutics stock rises on positive DM1 trial results
- Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
- Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
- Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
- Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. — Lancet Child Adolesc Health 2026 Oct PMID 42600624
- Defining the therapeutic corridor of stability in enzyme replacement therapy for Pompe disease: a position statement. — Orphanet J Rare Dis 2026 Jul 28 PMID 42538546
- HSP90 inhibition partially rescues alternative splicing dysregulation in cell models of myotonic dystrophy. — J Biol Chem 2026 Sep PMID 42486259
- Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up. — Cardiol Ther 2026 Sep PMID 42384320
- Simultaneous Determination of Four Per- and Polyfluoroalkyl Substances (PFAS) in DHA Products using LC-MS/MS for Quality Control and Risk Assessment. — J AOAC Int 2026 Jun 2 PMID 42226021
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Dyne Therapeutics.
Full DYN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.